Lorastad D

Lorastad D containing desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity, are indicated for the relief of symptoms associated with allergic rhinitis and urticaria.

Pack size Box of 30 tablets, 100 tablets
Shelf-life 24 months
Composition Desloratadine
Dosage forms and strengths Film-coated tablet: 5 mg
Product code :



The relief of symptoms associated with allergic rhinitis and urticaria.


  • Adults and adolescents (12 years of age and over): 1 tablet once a day.
  • Intermittent allergic rhinitis (presence symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
  • In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure period.
  • Patients with hepatic impairment or renal impairment: The recommended dose is 5 mg, taken once every 2 days (taken every other day).


Lorastad D is orally administered, regardless to meals.

Known hypersensitivity to desloratadine, loratadine, or any ingredient in the formulation.


  • Fatigue, dry mouth and headache.


  • Hallucinations, dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures; tachycardia, palpitations;
  • Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea;
  • Elevations of liver enzymes, increased bilirubin, hepatitis;
  • Myalgia;
  • Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnea, pruritus, rash, and urticaria).
  • The safety and efficacy of Lorastad D in children below the age of 12 years have not been established.
  • In the case of severe renal insufficiency, desloratadine should be used with caution.
  • Desloratadine should be administered with caution in patients with medical or familial history of seizures, patients with severe renal impairment.
  • The use of Lorastad D during pregnancy in breastfeeding women is not recommended.
  • Patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines. Patients should be aware of how they react to drug before driving or operating machinery.